anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to substituted cytisine compounds that are useful in treating diseases impacted by a nicotinic ACh receptor. One aspect of the invention relates to 10-substituted cytisine compounds. In certain instances, the cytisine is substituted in the 10-position by an alkyl, aryl or aralkyl group. The present invention also relates to a pharmaceutical composition comprises the substituted cytisine compound or the 10- substituted cytisine compound. The invention also relates to a method of modulation a nicotinic ACh receptor in a mammal, comprising the step of administering to a mammal in need thereof a therapeutically effective amount of a substituted cytisine. In certain instances, the substituted cytisine is a 10-substituted cytisine. Another aspect of the present invention relates a method of treating a disease impacted by a nicotinic ACh receptor, comprising the step of administering to a mammal in need thereof a therapeutically effective amount of a substituted cytisine. In certain instances, the substituted cytisine is a 10-substituted cytisine.
Prolactin has been recognized as neuroprotective hormone against various types of neuronal damage. This study was aimed to determine if prolactin protects against streptozotocin injury. A series of experiments were performed to determine neuronal survival by counting total neurons in medial hippocampus cortex and cerebellum. Astrogliosis was determined by immunofluorescence assays using GFAP, and behavioral improvement by prolactin after neuronal damage was determined by open-field and light-dark box tests. Results demonstrated that prolactin induced significant neuronal survival in both the hippocampus and cortex, but not in the cerebellum. No increase in astrogliosis was identified, but a significant reduction in anxiety levels was observed. Overall data indicate that prolactin may protect against a complex form of cell damage including oxidant stress and metabolic disruption by streptozotocin. Prolactin may be helpful strategy in the treatment of neuronal damage in neurological diseases.
Participants in the Nintendo Wii group were included to exercise program that consisted of 16 individual PT-supervised sessions (two 60-minute sessions/week), which were prepared to improve balance. Each session started with 10 minutes of non-resistance cycling work for warm-up.
This comprehensive review explores vimentin as a pivotal therapeutic target in cancer treatment, with a primary focus on mitigating metastasis and overcoming drug resistance. Vimentin, a key player in cancer progression, is intricately involved in processes such as epithelial-to-mesenchymal transition (EMT) and resistance mechanisms to standard cancer therapies. The review delves into diverse vimentin inhibition strategies. Precision tools, including antibodies and nanobodies, selectively neutralize vimentin's pro-tumorigenic effects. DNA and RNA aptamers disrupt vimentin-associated signaling pathways through their adaptable binding properties. Innovative approaches, such as vimentin-targeted vaccines and microRNAs (miRNAs), harness the immune system and post-transcriptional regulation to combat vimentin-expressing cancer cells. By dissecting vimentin inhibition strategies across these categories, this review provides a comprehensive overview of anti-vimentin therapeutics in cancer treatment. It underscores the growing recognition of vimentin as a pivotal therapeutic target in cancer and presents a diverse array of inhibitors, including antibodies, nanobodies, DNA and RNA aptamers, vaccines, and miRNAs. These multifaceted approaches hold substantial promise for tackling metastasis and overcoming drug resistance, collectively presenting new avenues for enhanced cancer therapy.
OBJECTIVES: Recurrence or tumor metastasis and drug resistance remain the major challenge in the treatment of thyroid cancer. It is needed to identify novel drug targets for thyroid cancer.
METHODS: Summary data-based Mendelian randomization (SMR) and colocalization analysis were performed to evaluate the associations between gene methylation, expression, protein levels with thyroid cancer. We additionally performed protein-protein interaction (PPI) network, gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) analyses to further explore the potential roles of identified genes in thyroid cancer.
RESULTS: SDCCAG8 and VCAM1 genes were associated with risk of thyroid cancer with tier 1 evidence, while TCN2 gene was with tier 3 evidence. SDCCAG8 gene was associated with risk of papillary thyroid cancer with tier 1 evidence. At the level of circulating proteins, genetically predicted higher levels of SDCCAG8 (OR = 0.46, 95% CI 0.34-0.64) and VCAM1 (OR = 0.21, 95% CI 0.10-0.45) were inversely associated with thyroid cancer risk; higher level of TCN2 was associated with an increased risk of thyroid cancer (OR = 1.30, 95% CI 1.15-1.47); and the higher level of SDCCAG8 (OR = 0.40, 95% CI 0.28-0.58) was associated with a decreased risk of papillary thyroid cancer. The bioinformatics analysis showed that SDCCAG8, VCAM1 and TCN2 might play roles in immune-related pathways.
CONCLUSION: SDCCAG8, VCAM1 and TCN2 genes were associated with thyroid cancer risk with evidence at multi-omics levels. There were potential roles of SDCCAG8, VCAM1 and TCN2 in immune-related pathways. Our findings might improve the understanding of the pathogenesis of thyroid cancer and discovery of novel potential drug targets for this disease.
The study will be a single-blind, step-wise dose escalation, placebo controlled study in healthy subjects consisting of up to 3 dose steps of DAA-I. In the sequential step wise design, a single dose of DAA-I or placebo will be administered to 6 subjects for one treatment group. For each dose step, 4 subjects will receive DAA-I and 2 subjects will receive placebo. Subjects will be randomly allocated to one dose step. Step One would have to be completed before Step Two. Escalation up to Step Two and subsequent steps would depend on the safety results from the preceding step(s). There will be an interval of 6 hours between the dosing of the first and second DAA-I-treated volunteers of each cohort to allow for early cardiovascular monitoring. Only if there are no safety signals identify from these subjects as assessed by the Safety Review Committee can simultaneous dosing of the remaining volunteers be carried out.
PCT No. PCT/EP91/01513 Sec. 371 Date Jun. 6, 1992 Sec. 102(e) Date Jun. 6, 1992 PCT Filed Aug. 9, 1991 PCT Pub. No. WO92/03551 PCT Pub. Date Mar. 5, 1992The invention provides recombinant DNA molecules which code for proteins or polypeptides that exhibit the antigenicity of a P14 allergen of birch Betula verrucosa and other plants of the order Fagales, and for polypeptides comprising at least one epitope thereof, as well as nucleic acids which under stringent conditions hybridize with such DNA sequences or are derivable from such sequences by degeneracy of the genetic code. A method is provided that permits purification of P14 allergens or cross-reactive allergens by means of binding to poly(L-proline). In addition, methods are described for making the proteins and polypeptides coded by these DNA molecules and their use in the diagnosis or therapy of allergic diseases.
Blast-induced traumatic brain injury is typically regarded as a signature medical concern for military personnel who are exposed to explosive devices in active combat zones. However, soldiers as well as law enforcement personnel may be repeatedly exposed to low-level blasts during training sessions with heavy weaponries as part of combat readiness. Service personnel who sustain neurotrauma from repeated low-level blast (rLLB) exposure do not display overt pathological symptoms immediately but rather develop mild symptoms including cognitive impairments, attention deficits, mood changes, irritability, and sleep disturbances over time. Recently, we developed a rat model of rLLB by applying controlled low-level blast pressures (≤ 70 kPa) repeated five times successively to mimic the pressures experienced by service members. Using this model, we assessed anxiety-like symptoms, motor coordination, and short-term memory as a function of time. We also investigated the role of the NLRP3 inflammasome, a complex involved in chronic microglial activation and pro-inflammatory cytokine interleukin (IL)-1β release, in rLLB-induced neuroinflammation. NLRP3 and caspase-1 protein expression, microglial activation, and IL-1β release were examined as factors likely contributing to these neurobehavioral changes. Animals exposed to rLLB displayed acute and chronic short-term memory impairments and chronic anxiety-like symptoms accompanied by increased microglial activation, NLRP3 expression, and IL-1β release. Treatment with MCC950, an NLRP3 inflammasome complex inhibitor, suppressed microglial activation, reduced NLRP3 expression and IL-1β release, and improved short-term memory deficits after rLLB exposure. Collectively, this study demonstrates that rLLB induces chronic neurobehavioral and neuropathological changes by increasing NLRP3 inflammasome protein expression followed by cytokine IL-1β release.
Scaffolds for tissue engineering, and methods and systems for manufacturing the same. The starting material used to manufacture the scaffolds may include a needled non- woven sheet, or a batt of fibers. In either case, the starting material includes a bioabsorbable polymer, such as polyglycolic acid or poly-L-lactide. This allows the scaffold to dissolve when exposed to water (e.g., when placed in the body). The starting material is needled into a three dimensional shape that is substantially seamless and then set with heat and pressure to provide substantially uniform thickness and density. This affords an improved substrate on which to place cells that will form the tissue.
Technologies for the sensing of biofeedback signals of a user include a body area network (BAN) system comprising one or more biofeedback sensors and one or more BAN controllers. The biofeedback sensors are configured to sense BAN signals, which may include biofeedback signals and body-coupled communication (BCC) signals. To facilitate communication, the biofeedback sensors may demultiplex the sensed BAN signals into biofeedback signals and incoming BCC signals. Similarly, the biofeedback sensors may multiplex outgoing BCC signals with sensed biofeedback signals. The BAN controller may communicate in a similar manner. Additionally, the BAN controller may process incoming BCC signals and provide feedback to the user based on BCC signals received from the biofeedback sensors.
A system includes an optical examination device and an eye-examination provider device remote from the optical examination device. The optical examination device includes a frame, which, in operation, positions the optical examination device with respect to a eyes of a patient. A plurality of sensors are embedded in the frame and sense data related to the eyes of the patient. Processing circuitry also is embedded in the frame and coupled to the plurality of sensors. A communication link is established between the optical examination device and the eye-examination provider device. The processing circuitry of the optical examination device executes optical examination routines on the patient using the plurality of sensors. The processing circuitry controls the optical examination routines using control signals received from the remote eye-examination provider device via the communication network.
Provided herein are compressed plant material assemblies, as well as apparatuses and methods for forming compressed plant material assemblies. A compressed plant material assembly includes plant material such as smokable cannabis plant material. The plant material is compressed into a form such as a ball, with a wick disposed partially within the ball of compressed plant material. The apparatus includes a base, a lid, and a plunger. The base includes a mold cavity with a major portion for holding the plant material, and a minor portion for holding the wick partially inserted in the plant material. The lid, when applied to the base, does not enclose the major portion of the mold cavity, such that the plant material can be compressed with the plunger.
The study is designed as a prospective, open enrollment clinical investigation involving multiple clinical study sites in the United States and Germany. Subjects will be competitively enrolled at multiple sites until at least 50 invasive colorectal adenocarcinoma cases identified by screening colonoscopy and verified by clinical and histopathological examination have been enrolled. The primary objective of the investigation is to evaluate and describe the clinical performance of the Septin 9 Biomarker for detecting the 50 individuals with invasive colorectal adenocarcinoma identified in this population representative of the US screening guideline eligible population. Secondary objectives will be to evaluate and describe performance characteristics of the biomarker in individuals with adenomatous polyps 10 mm or larger, flat lesion (s) or non-invasive adenocarcinoma.

Collaborating sites will identify and contact patients scheduled for screening colonoscopy. These patients may be screened by the PI or designee to determine the patients' appropriateness for, and interest in, study participation. Study site personnel will meet with patients meeting eligibility guidelines and offer them participation. Patients interested in participation and who provide written informed consent will be enrolled as Subjects in the study.
FIELD: veterinary virology. SUBSTANCE: method involves assay of antirabies virus-neutralizing antibodies by method of inhibition of fluorescence foci. Analyzed serum is mixed with an equal volume of attenuated strain of rabies virus TC-80 and incubated at 37 C for 90 min. Then reaction mixture is added to transplanted culture of saiga kidney cells, cell culture is fixed and antirabies immunoglobulins labeled with FITZ are applied. Reaction is estimated by inhibition of fluorescence foci in cell culture. Invention provides safety, sensitive and rapid method of assay of antirabies virus-neutralizing antibodies in vitro which shows correlation with titration results in experiments in white mice. EFFECT: improved method of assay, decreased cost. 1 tbl, 2 ex
After a stroke, antagonist muscle activation during agonist command impedes movement. This study compared measurements of antagonist muscle activation using surface bipolar EMG in the gastrocnemius medialis (GM) and high-density (HD) EMG in the GM and soleus (SO) during isometric submaximal and maximal dorsiflexion efforts, with knee flexed and extended, in 12 subjects with chronic hemiparesis. The coefficients of antagonist activation (CAN) of GM and SO were calculated according to the ratio of the RMS amplitude during dorsiflexion effort to the maximal agonist effort for the same muscle. Bipolar CAN (BipCAN) was compared to CAN from channel-specific (CsCAN) and overall (OvCAN) normalizations of HD-EMG. The location of the CAN centroid was explored in GM, and CAN was compared between the medial and lateral portions of SO. Between-EMG system differences in GM were observed in maximal efforts only, between BipCAN and CsCAN with lower values in BipCAN (p < 0.001), and between BipCAN and OvCAN with lower values in OvCAN (p < 0.05). The CAN centroid is located mid-height and medially in GM, while the CAN was similar in medial and lateral SO. In chronic hemiparesis, the estimates of GM hyperactivity differ between bipolar and HD-EMGs, with channel-specific and overall normalizations yielding, respectively, higher and lower CAN values than bipolar EMG. HD-EMG would be the way to develop personalized rehabilitation programs based on individual antagonist activations.
PURPOSE: Provided is an anticancer composition containing chopped or grounded root of Pulsatillae radix and/or Ulmaceae cortex, and optionally more than one of Ginseng radix and Glycyrrhizae radix. Such anticancer composition can be stored for several years stably without losing its medicinal efficacious. CONSTITUTION: 0-100 parts by weight of Pulsatillae radix: Pulsatilla Koreana nakai, Pursatilla cernua, Pulsatilla danurica, Pulsatilla ratensis etc.; as a main component and 0-100 parts by weight of Ulmaceae cortex are extracted by using solvent at no more than 60°C, filtered and freeze dried, and then a complement is added, or the complement is firstly added to the extract then filtered and freeze dried for pharmaceutical preparation. The solvent can be one of water, alcohol, acetone and ethylacetate, or mixture of such solvents. Armeniacae semen, Ginseng radix and Glycyrrhizae radix can be added as complements.
The present invention relates to traditional Chinese medicine for fumigating and washing piles, which comprises the ingredients of 15 to 20 grams of blue vitriol, 15 to 20 grams of ledebouriella root, 15 to 20 grams of rhizoma kaempferiae, 15 to 20 grams of pueraria root and 15 to 20 grams of halite. The five ingredients are mixed and filled in a gauze bag which is sealed, and the gauze bag with the five ingredients is put in a can, a casserole or ceramic ware. Water is added for decocting the ingredients for 10 to 20 minutes to obtain the traditional Chinese medicine for fumigating and washing piles, wherein the quantity of the added water meets the requirement of immersing the ingredients. When in use, the hot steam of medical liquid is fumigated at an affected part; when the temperature of the medical liquid is eligible, the affected part is washed by the medical liquid. Each portion of the medical liquid can be repeatedly decocted for three days, and is continuously used twice every day. The traditional Chinese medicine of the present invention has the advantages of quick curative effect and no recurrence.
The sample includes all childhood cochlear implant (CI) recipients at Oslo University Hospital in Norway from 1988-2012. The participant must have at least one year of CI-user time. Possible sample size is 530 children. The age span is from 1 to 50 years.
The utility model discloses an artemisinine compound suppository for treatment of female genital diseases, which comprises a main suppository body. The main suppository body is provided with a through groove, and the through groove is of a nonconventional shape or a straight groove with a closed extending end. The through groove can comprise more than two communicated through grooves with any shape or can be the straight groove. With the through groove, the utility model realizes the easy pushing and pulling of such items as cotton swabs with the diameters smaller than the aperture of the through groove. When being needed, the artemisinine compound suppository is arranged in the vagina, and the cotton swab is inserted in the through groove, the artemisinine compound suppository is pushed by the cotton swab into the vagina, and then the cotton swab is pulled out of the through groove and the vagina. The utility model has the advantages of novel structure, safe and hygienic operation and convenient and rapid use, and can be easily absorbed by the human body.
This invention is related to adenoviral (Ad) vectors and their applications in the field of genetic medicine, including, but not limited to, gene vaccination, gene transfer, gene therapy, and the like. More specifically, this invention is related to the Ad vectors that carry the minimal cis-element of the Ad genome (minimal Ad vector) and are capable of delivering about 36 kb to about 38 kb of heterologous DNA. The generation and propagation of the minimal Ad vectors require trans-complementation of a packaging-attenuated and replication-defective helper Ad (helper) in an Ad helper cell line.  
     This invention further comprises minimal adenoviral vectors for use in the treatment or prevention of disease or other medical conditions, methodologies for generating such vectors and animal test systems for in vivo evaluation of such Ad vectors. More specifically, this invention describes HIV and/or HPV Ad vectors that contain minimal cis-elements of the Ad genome and comprise HIV and/or HPV nucleic acid sequence with other supporting and/or complementing nucleic acid elements up to about 36 kb to about 38 kb. The HIV and/or HPV minimal Ad may be generated and preferentially amplified through the assistance of a packaging-attenuated helper Ad and a helper cell line. This invention also discloses designs and methods for testing such minimal Ad vectors in vivo.
Chronic Obstructive Pulmonary Disorder (COPD) is a common preventable and treatable disease that is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Hypoxia caused by restrictive airflow is one of the symptoms of COPD. Hypoxia can affect the inner ear and vestibular nuclei. Also, balance impairment can be caused by hypoxia. Previous studies show that balance affected negatively in COPD patients. The aim of this study is to investigate of vestibular system influence in individuals with COPD. A total of 10 COPD patients and 10 healthy adults will include the study. This research is planned to be carried out as a cross-sectional/descriptive research. It's planned as a pilot study. Respiratory functions (respiratory function test), vestibular functions (head shake test, head trust test, unterberger test) and postural stability (sensory organization test) of participants will be assessed.Comparisons between study and control groups will be made with independent samples t-test for parametric values and Mann Whitney U for non-parametric values.